Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating restated by Jefferies Group LLC in a report released on Friday. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.

ZTS has been the subject of a number of other reports. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub lowered shares of Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley increased their price objective on shares of Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $67.06.

Shares of Zoetis (NYSE:ZTS) traded down $0.17 on Friday, reaching $69.13. 1,905,724 shares of the company’s stock were exchanged, compared to its average volume of 2,817,385. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis has a twelve month low of $48.24 and a twelve month high of $70.48. The stock has a market cap of $33,540.00, a price-to-earnings ratio of 31.89, a P/E/G ratio of 2.03 and a beta of 1.02.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the firm posted $0.52 EPS. The company’s revenue was up 8.5% on a year-over-year basis. equities research analysts expect that Zoetis will post 2.36 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Zoetis Inc. (ZTS) Rating Reiterated by Jefferies Group LLC” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/10/zoetis-inc-zts-rating-reiterated-by-jefferies-group-llc.html.

A number of institutional investors and hedge funds have recently modified their holdings of ZTS. Northwestern Mutual Wealth Management Co. lifted its position in Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after buying an additional 230 shares during the last quarter. Harfst & Associates Inc. lifted its position in Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after buying an additional 260 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Zoetis in the second quarter worth $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after buying an additional 1,360 shares during the last quarter. Finally, Peddock Capital Advisors LLC bought a new stake in Zoetis in the second quarter worth $140,000. Institutional investors own 92.90% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.